| RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion |
2020-06-22 |
| Univ Bochum–Max Planck: antibiotics research, 202006– collab establishment CESAR Center for Antibiotics Research at Univ Bochum with LDC |
2020-06-18 |
| Univ Bochum–North Rhine-Westphalia (govt): grant, 202006– grant €4m from NRW + EFRO for establishment CESAR Center for Antibiotics Research with LDC |
2020-06-18 |
| China Grand Pharma–eTheRNA: mRNA technology, 202006– collab outline terms of potential strategic partnership R+D + production + sales in Greater China |
2020-06-16 |
| DiogenX–Advent France Biotechnology: investment, 202006 seed financing round totalling €4.5m incl investor Advent France Biotechnology |
2020-06-16 |
| DiogenX–Andrew Lloyd Associates: public relations, 202006 service existent by ALA |
2020-06-16 |
| DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF |
2020-06-16 |
| DiogenX–Juvenile Diabetes Research Foundation: investment, 202006 seed financing round totalling €4.5m incl investor JDRF T1D Fund |
2020-06-16 |
| DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund |
2020-06-16 |
| eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity |
2020-06-16 |
| eTheRNA–Boehringer: investment, 202006 financing round Series B totalling €34m incl existing investor BIVF |
2020-06-16 |
| eTheRNA–China Grand Pharma: investment, 202006 financing round Series B totalling €34m incl new investor Grand Decade |
2020-06-16 |
| eTheRNA–Flanders (govt): investment, 202006 financing round Series B totalling €34m incl existing investor PMV |
2020-06-16 |
| eTheRNA–Fund+: investment, 202006 financing round Series B totalling €34m incl existing investor Fund+ |
2020-06-16 |
| eTheRNA–Life Sciences Partners: investment, 202006 financing round Series B totalling €34m incl existing investor LSP |
2020-06-16 |
| eTheRNA–Novalis LifeSciences: investment, 202006 financing round Series B totalling €34m incl new investor Novalis LifeSciences LLC |
2020-06-16 |
| eTheRNA–Omega Funds: investment, 202006 financing round Series B totalling €34m incl existing investor Omega Funds |
2020-06-16 |
| eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors |
2020-06-16 |
| eTheRNA–Yijing Capital: investment, 202006 financing round Series B totalling €34m incl new investor Yijing Capital |
2020-06-16 |
| GSK–Ideaya Biosciences: synthetic lethality, 202006– collab strategic partnership ww $100m upfront + milestones + royalties |
2020-06-16 |
| Ideaya Biosciences–GSK: investment, 202006 direct private placement $20m common stock purchase by GSK |
2020-06-16 |
| MedinCell–SEVERAL: investment, 202006 capital increase €15.6m from French + international investors |
2020-06-16 |
| Ona Therapeutics–Alta Life Sciences: investment, 202006 financing round Series A totalling €30m incl new investor Alta Life Sciences |
2020-06-16 |
| Ona Therapeutics–Asabys Partners: investment, 202006 financing round Series A totalling €30m incl existing investor Sabadell Asabys |
2020-06-16 |
| Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 |
2020-06-16 |
| Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ |
2020-06-16 |
| Ona Therapeutics–Optimum Strategic Communications: public relations, 202006 service existent by Optimum |
2020-06-16 |
| Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m |
2020-06-16 |
| Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital |
2020-06-16 |
| Qurient–Max Planck: proteasome inhibitors, 2012006– collab develop + license + founding of joint venture QLi5 Therapeutics GmbH |
2020-06-16 |
| CureVac–Germany (govt): investment, 202006 investment €300m direct equity investment by KfW |
2020-06-15 |
| Epsilen Bio–Sofinnova: investment, 202006c seed financing €2.3m from Sofinnova Partners through Sofinnova Telethon Fund |
2020-06-15 |
| Bit Bio–ARCH Venture: investment, 202006 financing round Series A totalling $41.5m incl co-investor Arch Venture Partners |
2020-06-13 |
| Bit Bio–BY Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor BlueYard Capital |
2020-06-13 |
| Bit Bio–Foresite Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor Foresite Capital |
2020-06-13 |
| Bit Bio–Mission Group: public relations, 202006 service existent by April Six |
2020-06-13 |
| Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Bob Nelsen |
2020-06-13 |
| Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Jim Tananbaum |
2020-06-13 |
| Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Rick Klaunser |
2020-06-13 |
| Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum |
2020-06-13 |
| JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV |
2020-06-12 |
| Lexent Bio–Roche: investment, 202006 acquisition of Lexent Bio by Foundation Medicine |
2020-06-12 |
| Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics |
2020-06-11 |
| 10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM |
2020-06-10 |
| Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF |
2020-06-10 |
| Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV |
2020-06-10 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investorj JnJ Innovation |
2020-06-10 |
| Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Protera–SEVERAL: investment, 202006 financing round Series A $5.6m led by Sofinnova Partners + incl existing investor SOSV |
2020-06-10 |
| Ysios Capital–SEVERAL: investment, 202006 first closing €155m of Ysios BioFund III with target size of €200m |
2020-06-10 |
| Royalty Pharma–AiCuris: letermovir, 202006 acquisition of partial royalty interest on letermovir for one-time payment of $220m by Royalty Pharma |
2020-06-09 |
| Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications |
2020-06-08 |
| Tropic Biosciences–SEVERAL: investment, 202006 financing round Series B $28.5m led by Temasek |
2020-06-04 |
| Tropic Biosciences–Temasek: investment, 202006 financing round Series B totalling $28.5m incl new + lead investor Temasek |
2020-06-04 |
| Base Genomics–SEVERAL: investment, 202006 seed financing round £9m ($11m) led by Oxford Sciences Innovation |
2020-06-03 |
| Base Genomics–Univ Oxford: investment, 202006 seed financing round totalling £9m incl lead investor Oxford Sciences Innovation |
2020-06-03 |
| Base Genomics–Zyme Communications: public relations, 202006 service existent by Zyme |
2020-06-03 |
| BRAIN–SEVERAL: investment, 202006 private placenment €14.94m with 1.8m new shares at €8.3/share |
2020-06-03 |
| Hyloris Pharmaceuticals–SEVERAL: investment, 202006– IPO with 5m+750k shares at price range of €10.0 to €11.5 at Euronext Brussels |
2020-06-03 |
| NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures |
2020-06-03 |
| Prilenia–Forbion: investment, 202006 financing round Series A totalling $62.5m incl new + lead investor Forbion |
2020-06-03 |
| Prilenia–Genworks 2: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Genworks 2 |
2020-06-03 |
| Prilenia–Instinctif Partners: public relations, 202006 service existent by Instinctif |
2020-06-03 |
| Prilenia–Morningside: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Morningside Venture Investments |
2020-06-03 |
| Prilenia–Sectoral Asset Management: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Sectoral Asset Management |
2020-06-03 |
| Prilenia–SEVERAL: investment, 202006 financing round Series A $62.5m led by new investor Forbion |
2020-06-03 |
| Prilenia–Talisman Capital Partners: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Talisman Capital Partners |
2020-06-03 |
| AdvanceCor–Bavaria (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor Bayern Kapital |
2020-06-02 |
| AdvanceCor–First Capital Partner: investment, 202006 financing round totalling €3.9m incl co-investor First Capital Partner |
2020-06-02 |
| AdvanceCor–Germany (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor KfW Bank |
2020-06-02 |
| AdvanceCor–MIG Fonds: investment, 202006 financing round totalling €3.9m incl existing + lead investor MIG AG |
2020-06-02 |
| AdvanceCor–Occident Group: investment, 202006 financing round totalling €3.9m incl existing + co-investor Occident |
2020-06-02 |
| AdvanceCor–SEVERAL: investment, 202006 financing round €3.9m led by MIG AG |
2020-06-02 |
| Rigenerand–Image Box: public relations, 202005– supply service by Image Box PR |
2020-05-29 |
| Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility |
2020-05-27 |
| Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital |
2020-05-27 |
| Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF |
2020-05-27 |
| Kumovis–Renolit: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Renolit SE |
2020-05-27 |
| Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures |
2020-05-27 |
| Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures |
2020-05-27 |
| MedinCell–SEVERAL: credit, 202005– state guaranteed PGE loan €10.9m at 0.25% up to 5y from Banque Populaire du Sud + BNP Paribas |
2020-05-27 |
| Accure Therapeutics–SEVERAL: investment, 202005 financing round Series A €7.6m led by Alta Life Sciences with support from CDTI |
2020-05-26 |
| Argenx–SEVERAL: investment, 202005 global offering $862.5 via ADS offering in US + private placement in Europe |
2020-05-26 |
| Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital |
2020-05-26 |
| Spindiag–Baden-Württemberg (govt): grant, 202004 grant €6m for Spindiag + HSI-IMIT from Ministry of Economic Affairs |
2020-05-26 |
| Spindiag–SEVERAL: investment, 202005 financing round Series B €16.3m with investors WBG Pflegeheime + Think-Health Ventures et al. |
2020-05-26 |
| Spindiag–Think.Health Ventures: investment, 202005 financing round Series B totalling €16.3m incl new investor Think.Health Ventures |
2020-05-26 |
| Spindiag–WBG Pflegeheime: investment, 202005 financing round Series B totalling €16.3m incl existing investor WBG Pflegeheime |
2020-05-26 |
| Sterna Biologicals–MC Services: public relations, 202005 service existent by MC Services |
2020-05-26 |
| Sterna Biologicals–SEVERAL: investment, 202005 private placement €12m with existing + new investors |
2020-05-26 |
| Themis Bioscience–Merck (US): investment, 202005– acquisition €na all remaing shares of Themis via Merck subsidiary |
2020-05-26 |
| Tollys–Andrew Lloyd Associates: public relations, 202005 service existent by ALA |
2020-05-26 |
| Tollys–SEVERAL: investment, 202005 financing round Series A €2.3m bringing total raised since founding 2015 to €6.4m |
2020-05-26 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
